tradmap

STLN Earnings Starling Oncology, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$1 -$0 $0 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $251M $503M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$83M $32B $65B $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 -$0 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $81M $161M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$20M -$10M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–28 of 28
Q2 20262026-06-30-0.082026-08-0610-Q
Q1 20262026-03-31-0.022026-05-0710-Q
Q4 2025 (derived)2025-12-31-0.042026-03-1210-K
FY 20252025-12-31-0.542026-03-1210-K
Q3 20252025-09-30-0.142025-11-1310-Q
Q2 20252025-06-30-0.152025-08-1310-Q
Q1 20252025-03-31-0.212025-05-1410-Q
Q4 2024 (derived)2024-12-31-0.142025-03-2610-K
FY 20242024-12-31-0.712025-03-2610-K
Q3 20242024-09-30-0.182024-11-1310-Q
Q2 20242024-06-30-0.172024-08-1310-Q
Q1 20242024-03-31-0.222024-05-1410-Q
Q4 2023 (derived)2023-12-31-0.212024-03-2810-K
FY 20232023-12-31-0.922024-03-2810-K
Q3 20232023-09-30-0.192023-11-0810-Q
Q2 20232023-06-30-0.192023-08-0910-Q
Q1 20232023-03-31-0.332023-05-1010-Q
Q4 2022 (derived)2022-12-31-0.192023-03-1610-K
FY 20222022-12-31-0.212023-03-1610-K
Q3 20222022-09-30-0.172022-11-0910-Q
Q2 20222022-06-30-0.062022-08-0910-Q
Q1 20222022-03-310.212022-05-1010-Q
Q4 2021 (derived)2021-12-31-0.142022-03-1110-K
FY 20212021-12-31-0.162022-03-1110-K
Q3 20212021-09-30-0.05——
Q2 20212021-06-300.05——
Q1 20212021-03-31-0.02——
FY 20202020-12-31-0.24——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.